[1]杨 欢,朱 梅,张改琴,等.多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果[J].医学信息,2022,35(19):121-123.[doi:10.3969/j.issn.1006-1959.2022.19.034]
　YANG Huan,ZHU Mei,ZHANG Gai-qin,et al.Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis[J].Journal of Medical Information,2022,35(19):121-123.[doi:10.3969/j.issn.1006-1959.2022.19.034]
点击复制

多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年19期
页码:
121-123
栏目:
药物与临床
出版日期:
2022-10-01

文章信息/Info

Title:
Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis
文章编号:
1006-1959（2022）19-0121-03
作者:
杨 欢; 朱 梅; 张改琴; 等
（徐州市肿瘤医院肿瘤内科，江苏 徐州 221000）
Author(s):
YANG Huan; ZHU Mei; ZHANG Gai-qin; et al.
(Department of Oncology,Xuzhou Cancer Hospital,Xuzhou 221000,Jiangsu,China)
关键词:
胃癌腹膜转移; 阿帕替尼; 多西他赛; 替吉奥
Keywords:
Peritoneal metastasis of gastric cancer; Apatinib; Docetaxel; Tegafur
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2022.19.034
文献标志码:
A
摘要:
目的 研究多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者效果。方法 选取2016年1月-2018年1月我院就诊的胃癌腹膜转移患者60例，随机分为对照组和观察组，每组30例。对照组给予多西他赛腹腔灌注加静脉化疗辅以口服替吉奥胶囊，观察组在对照组基础上加用阿帕替尼治疗，比较两组临床疗效、CEA、CA125、CA19-9、不良反应发生率及生存率。结果 观察组总有效率为93.33%，高于对照组的66.67%（P＜0.05）；两组治疗后CEA、CA125、CA19-9水平低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应总发生率及1、2、3年生存率高于对照组，但差异无统计学意义（P＞0.05）。结论 采用多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果理想，能有效降低肿瘤标志物水平，延长生存期，安全性较好。
Abstract:
Objective To study the effect of intraperitoneal perfusion of docetaxel plus intravenous chemotherapy and oral administration of tegafur combined with apatinib in the treatment of gastric cancer patients with peritoneal metastasis.Methods From January 2016 to January 2018,60 patients with peritoneal metastasis of gastric cancer in our hospital were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with docetaxel intraperitoneal perfusion plus intravenous chemotherapy combined with oral tegafur capsule. The observation group was treated with apatinib on the basis of the control group. The clinical efficacy, CEA, CA125, CA19-9, incidence of adverse reactions and survival rate were compared between the two groups.Results The total effective rate of the observation group was 93.33%, which was higher than 66.67% of the control group (P<0.05). After treatment, the levels of CEA, CA125 and CA19-9 in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The total incidence of adverse reactions and The 1-, 2-and 3-year survival ratesin the observation group was higher than that in the control group, but the difference was not statistically significant (P>0.05). Conclusion Docetaxel intraperitoneal infusion combined with intravenous chemotherapy and oral tegafur combined with apatinib are effective in the treatment of gastric cancer with peritoneal metastasis, which can effectively reduce the level of tumor markers, prolong the survival time and have good safety.

参考文献/References:

[1]毛争强,杜波涛,宰守峰.全腹腔镜远端胃癌根治术对胃癌疗效及患者血清相关指标和预后的影响[J].实用癌症杂志,2021,36(11):1834-1836,1840.[2]赵磊,黄涛,刘春庆.腹腔镜下远端胃癌根治术三种消化道重建方式的近期和远期疗效分析[J].北京医学,2021,43(3):220-223.[3]徐菁.阿帕替尼不良反应观察及其在胃癌治疗中的疗效相关性分析[D].济南:山东大学,2019.[4]Li J,Qin S,Xu J,et al.Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[J].J Clin Oncol,2016,34(13):1448-1454.[5]Wang KX,Cui TY,Yang XD,et al.Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial[J].Onco Targets Ther,2021,14:4859-4865.[6]Zheng Y,Yang X,Yan C,et al.Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial[J].Eur J Cancer,2020,130:12-19.[7]董祖木.六君子汤合益胃汤联合化疗治疗晚期胃癌临床观察[J].贵州医药,2021,45(6):903-904.[8]刘扬帆,万里新,屈中玉,等.腹腔恒温循环热灌注化疗治疗晚期胃癌伴腹水患者的临床疗效分析[J]. 现代诊断与治疗,2021,32(10):1569-1570.[9]]Kakuta T,Yabusaki H,Bamba T,et al.Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy[J].Int J Clin Oncol,2021,26(4):684-693.[10]黄超,金锷.替吉奥、氟尿嘧啶分别和多西他赛联合对高龄晚期胃癌患者的疗效比较[J].中国老年学杂志,2020,40(17):3638-3642.[11]Fujiwara Y,Takiguchi S,Nakajima K,et al.Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination[J].J Surg Oncol,2012,105(1):38-42.[12]Bando H,Yamada Y,Tanabe S,et al.Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer[J].Gastric Cancer,2016,19(3):919-926.[13]Scott LJ.Apatinib:A review in advanced gastric cancer and other advanced cancers[J].Drugs,2018,78(7):747-758.[14]Ratti M,Lampis A,Hahne JC,et al.Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches[J].Cell Mol Life Sci,2018,75(22):4151-4162.[15]蔡明志,王学军,刘勇,等.以替吉奥为基础联合阿帕替尼的三药方案在不可切除晚期胃癌转化治疗中的应用[J].中华胃肠外科杂志,2021,24(2):179-184.

相似文献/References:

[1]李 光.替吉奥联合阿帕替尼治疗晚期胰腺癌的疗效分析[J].医学信息,2018,31(16):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
　LI Guang.Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer[J].Journal of Medical Information,2018,31(19):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
[2]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(19):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
[3]王红艳,潘 利.自拟抑癌汤联合阿帕替尼治疗对中晚期胃癌患者的疗效及对血清CEA、CA199的影响[J].医学信息,2021,34(14):166.[doi:10.3969/j.issn.1006-1959.2021.14.047]
　WANG Hong-yan,PAN Li.Efficacy of Self-made Anti Cancer Soup Combined with Apatinib on Patients with Middle and Advanced Gastric Cancer and Its Effect on Serum CEA,CA199[J].Journal of Medical Information,2021,34(19):166.[doi:10.3969/j.issn.1006-1959.2021.14.047]
[4]徐帅帅,高 斌.TACE与阿帕替尼联合治疗中晚期肝细胞癌的疗效及安全性分析[J].医学信息,2022,35(06):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
　XU Shuai-shuai,GAO Bin.Analysis of the Efficacy and Safety of TACE Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(19):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
[5]何耀强,陈焕伟,杨少苏.载吡柔比星微球经导管肝动脉化疗栓塞术联合阿帕替尼在原发性肝癌患者介入治疗中的应用价值[J].医学信息,2024,37(01):125.[doi:10.3969/j.issn.1006-1959.2024.01.021]
　HE Yao-qiang,CHEN Huan-wei,YANG Shao-su.Application Value of Transcatheter Arterial Chemoembolization with Pirarubicin-loaded Microspheres Combined with Apatinib Therapy in the Interventional Treatment of Patients with Primary Liver Cancer[J].Journal of Medical Information,2024,37(19):125.[doi:10.3969/j.issn.1006-1959.2024.01.021]

更新日期/Last Update: 1900-01-01